Roadshow
GM-XANTHO
GM-XANTHO
The new drug GM-XANTHO developed by Xantho Biotechnology, is a non-steroidal cream for the treatment of Atopic Dermatitis (AD), plaque psoriasis and wound healing (pressure ulcer, diabetic wound, burn wound).
Non-steroidal cream with no side effects
Effective in treating skin inflammation and for wound healing
Phase IIa results are now available, preparing for Phase IIb clinical study
Available in large quantities with PIC/S GMP specifications
Available for out-licensing with rights in drug development and commercialization
Join us at BIO 2025, June 16-19 in Boston, where Xantho Biotechnology Co., LTD will be showcasing our cutting-edge solutions and services. We can't wait to connect with you to discuss how we're shaping the future of biotechnology. Find us at Booth 1645. See you there!
#BIO2025#TAIWAN PAVILION
Clinical Trial
Phase IIa (NCT04369846)
The efficacy and safety of GM-XANTHO in patients with mild-to-moderate atopic dermatitis have been evaluated in a completed double-blinded, placebo-controlled Phase IIa clinical trial. We are now preparing to advance to a Phase IIb clinical trial.
Patent
Patents for GM-XANTHO have been granted in the US, EU, Japan, Taiwan, India, China etc.
- Established 2014
- Company Xantho Biotechnology Co., LTD
- Telephone +886-2-2655-7790
- Email business@xanthobio.com
- Address Rm. ER15, 17F.-1, No. 3, Yuanqu St., Nangang Dist., Taipei City 11503, Taiwan
Established in 2014, Xantho Biotechnology Co., LTD is a research-oriented company specialized in developing new drugs in dermatology.